Optimal Strategix Group launches study matching app
Optimal Strategix Group (OSG), based in Newtown, Pa., has launched its CAVII app, available for download in the Apple App Store. CAVII is an iOS-based clinical study matching and analytics platform. Ushering in a new era of patient engagement, CAVII's aim is to revolutionize clinical studies through the use of analytics for superior patient matching. Through CAVII, clinical studies could become more cost-effective, efficient and ultimately more engaging and insightful for patients and clinicians.
Giri Iyer, OSG's executive vice president of analytics, said, "There's a simple truth about global healthcare: all of us will be patients in the future, and hopefully we'll enjoy more and more advanced solutions. However, studies show that an average clinical studies costs upwards of $2.5 billion dollars, and barely 10% of the clinical studies finish on time. 50% of patients in the U.S. simply don't know about clinical studies or how to sign up for one, leading to a massive problem with proper patient recruitment. Our mission with CAVII is to get patients worldwide involved in clinical studies, using analytics and a big data platform that OSG has developed. CAVII allows users to import their health data from thousands of top hospitals and medical facilities in the U.S. (an estimated 150 million electronic medical records) thanks to our partner, HumanAPI and their tremendous expertise."
Ashvanni Srivastava, executive vice president of OSG's Healthcare Practice, believes that CAVII will help ring in a new era of cost-effective patient controlled healthcare. Srivastava said, "Given the enormous expense involved with clinical studies, a 1% improvement in the current bureaucracy-heavy studies process will save the average pharmaceutical company $20-30 million a year. CAVII will put tools in the hands of patients so that they can manage their own studies journey, delivering a beneficial and cost-effective result for patients, clinicians and pharma companies."
Dr. R. Sukumar, OSG's founder and CEO, regards CAVII as a natural extension of OSG's core strengths, remarking that "We see the use of analytics in CAVII as a natural extension of our current business. Over the last decade, OSG has done over 600 studies with pharma and med devices for companies such as Johnson & Johnson, Medtronic/Covidien and BD (formerly Becton Dickinson). We've helped with all aspects of clinical research and drug or device commercialization studies, ranging from patient/clinician behavioral analytics, patient segmentation, disease segmentation and target product profiles. CAVII gives pharmaceutical companies the ability to complete clinical studies faster by recruiting and engaging patients effectively, and it uncovers deep, unique and actionable insights about human behavior."